Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2022-03-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities for Lepu Biopharma Co., Ltd., specifically focusing on authorized/registered share capital and issued shares as of February 28, 2022. It includes detailed tables on share capital, issued shares, and confirmations related to share issuance and listing compliance. The document is submitted to the Hong Kong Exchanges and Clearing Limited and references the Listing Date of the company's shares on the SEHK. The content is regulatory in nature, reporting share capital and share issuance movements, but it is not a financial report, earnings release, or management discussion. It is not a simple announcement or a brief summary but a formal regulatory filing reporting share capital movements and confirmations. This fits the category of a Regulatory Filing (RNS) as it does not match other more specific categories like Share Issue/Capital Change (SHA) because it is a monthly return report rather than a single announcement of a capital change event. Therefore, the best classification is Regulatory Filings (RNS).
2022-03-03 English
List of Directors and their Roles and Functions
Board/Management Information Classification · 100% confidence The document lists the members of the board of directors and their roles and functions, including committee memberships. It is a straightforward announcement of board composition and committee assignments without financial data or other report content. The document length is short (1344 characters), and it focuses solely on board/management information. Therefore, it fits the category of Board/Management Information (MANG).
2022-02-21 English
Terms of Reference for Remuneration and Appraisal Committee
Remuneration Information Classification · 95% confidence The document is titled 'REMUNERATION AND APPRAISAL COMMITTEE UNDER THE BOARD OF DIRECTORS TERMS OF REFERENCE' and details the composition, responsibilities, meetings, and procedures of the Remuneration and Appraisal Committee under the board of directors. It focuses on remuneration policies, appraisal standards, committee member duties, and governance related to executive compensation. There is no financial data, earnings information, or report publication mentioned. The content aligns with detailed compensation and governance practices for directors and senior management, which fits the definition of Remuneration Information filings. Therefore, the document is best classified as a Remuneration Information report (DEF 14A).
2022-02-21 English
Terms of Reference for Nomination Committee
Governance Information Classification · 95% confidence The document is titled 'Nomination Committee Under the Board of Directors Terms of Reference' for Lepu Biopharma Co., Ltd. It details the structure, responsibilities, composition, and procedures of the Nomination Committee under the board of directors. The content focuses on governance practices related to board nominations, committee meetings, and member duties. There is no financial data, earnings information, or regulatory filing announcements. The document is a governance-related policy document outlining internal rules and committee terms. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance content, not a brief announcement or report publication notice.
2022-02-21 English
Terms of Reference for Audit Committee
Governance Information Classification · 95% confidence The document is titled 'Audit Committee Under the Board of Directors Terms of Reference' and details the composition, responsibilities, and procedures of the audit committee of Lepu Biopharma Co., Ltd. It outlines governance and oversight functions related to audit, risk management, internal controls, and financial reporting. There are no actual financial statements, audit opinions, or results of audits presented. Instead, it is a governance document describing the audit committee's role and duties, which aligns with governance information about internal rules and board committee structures. Therefore, this document fits best under Governance Information (CGR).
2022-02-21 English
Articles of Association
Governance Information Classification · 100% confidence The document is titled 'Articles of Association' for Lepu Biopharma Co., Ltd. It contains detailed provisions about the company's governance structure, share issuance, board of directors, shareholders' meetings, financial accounting system, and other corporate governance matters. The content is a comprehensive set of internal rules and regulations governing the company rather than a financial report, announcement, or meeting material. It is not an Annual Report, Interim Report, Earnings Release, or any other financial disclosure. It is also not a proxy statement or voting results announcement. The document fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-02-21 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.